Nitai Roy1, Katsuki Ohtani1, Yoshihiko Hidaka2, Yoshiro Amano3, Yasuyuki Matsuda1, Kenichiro Mori1, Insu Hwang1, Norimitsu Inoue4, Nobutaka Wakamiya5. 1. Department of Microbiology & Immunochemistry, Asahikawa Medical University, Asahikawa 078-8510, Japan. 2. Department of Pediatrics, School of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. 3. Department of Pediatrics, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano 380-8582, Japan. 4. Department of Tumor Immunology, Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan. 5. Department of Microbiology & Immunochemistry, Asahikawa Medical University, Asahikawa 078-8510, Japan. Electronic address: wakamiya@asahikawa-med.ac.jp.
Abstract
BACKGROUND: Pentraxins (PTXs) are a superfamily of multifunctional conserved proteins involved in acute-phase responses. Recently, we have shown that collectin placenta 1 (CL-P1) and C-reactive protein (CRP) mediated complement activation and failed to form terminal complement complex (TCC) in normal serum conditions because of complement factor H inhibition. METHODS: We used CL-P1 expressing CHO/ldlA7 cells to study the interaction with PTXs. Soluble type CL-P1 was used in an ELISA assay for the binding, C3 and TCC deposition experiments. Furthermore, we used our previously established CL-P1 expressing HEK293 cells for the C3 fragment and TCC deposition assay. RESULTS: We demonstrated that CL-P1 also bound serum amyloid p component (SAP) and pentraxin 3 (PTX3) to activate the classical pathway and the alternative pathway using factor B. CRP and PTX3 further amplified complement deposition by properdin. We found that CRP and PTX3 recruit CFH, whereas SAP recruits C4 binding protein on CL-P1 expressing cell surfaces to prevent the formation of TCC in normal serum conditions. In addition, depletion of CFH, C4BP and complement factor I (CFI) failed to prevent TCC formation both in ELISA and cell experiments. Furthermore, soluble complement receptor 1, an inhibitor of all complement pathways prevents PTX induced TCC formation. CONCLUSION: Our current study hypothesizes that the interaction of pentraxins with CL-P1 is involved in complement activation. GENERAL SIGNIFICANCE: CL-P1 might generally inhibit PTX induced complement activation and host damage to protect self-tissues.
BACKGROUND:Pentraxins (PTXs) are a superfamily of multifunctional conserved proteins involved in acute-phase responses. Recently, we have shown that collectin placenta 1 (CL-P1) and C-reactive protein (CRP) mediated complement activation and failed to form terminal complement complex (TCC) in normal serum conditions because of complement factor H inhibition. METHODS: We used CL-P1 expressing CHO/ldlA7 cells to study the interaction with PTXs. Soluble type CL-P1 was used in an ELISA assay for the binding, C3 and TCC deposition experiments. Furthermore, we used our previously established CL-P1 expressing HEK293 cells for the C3 fragment and TCC deposition assay. RESULTS: We demonstrated that CL-P1 also bound serum amyloid p component (SAP) and pentraxin 3 (PTX3) to activate the classical pathway and the alternative pathway using factor B. CRP and PTX3 further amplified complement deposition by properdin. We found that CRP and PTX3 recruit CFH, whereas SAP recruits C4 binding protein on CL-P1 expressing cell surfaces to prevent the formation of TCC in normal serum conditions. In addition, depletion of CFH, C4BP and complement factor I (CFI) failed to prevent TCC formation both in ELISA and cell experiments. Furthermore, soluble complement receptor 1, an inhibitor of all complement pathways prevents PTX induced TCC formation. CONCLUSION: Our current study hypothesizes that the interaction of pentraxins with CL-P1 is involved in complement activation. GENERAL SIGNIFICANCE: CL-P1 might generally inhibit PTX induced complement activation and host damage to protect self-tissues.
Authors: Alanson W Girton; Narcis I Popescu; Ravi S Keshari; Tarea Burgett; Florea Lupu; K Mark Coggeshall Journal: Infect Immun Date: 2018-04-23 Impact factor: 3.441
Authors: Concepción Santiago-Fernández; Luis M Pérez-Belmonte; Mercedes Millán-Gómez; Inmaculada Moreno-Santos; Fernando Carrasco-Chinchilla; Amalio Ruiz-Salas; Luis Morcillo-Hidalgo; José M Melero; Lourdes Garrido-Sánchez; Manuel Jiménez-Navarro Journal: J Transl Med Date: 2019-03-20 Impact factor: 5.531
Authors: Jie Zhang; Lihong Song; Dennis V Pedersen; Anna Li; John D Lambris; Gregers Rom Andersen; Tom Eirik Mollnes; Ying Jie Ma; Peter Garred Journal: Elife Date: 2020-09-10 Impact factor: 8.140